Psychosis and catatonia in fragile X: Case report and literature review.

Intractable Rare Dis Res

MIND Institute, University of California Davis, Medical Center, Sacramento, USA; ; Department of Pediatrics, University of California Davis, Medical Center, Sacramento, USA;

Published: August 2015

Fragile X mental retardation 1 (FMR1) premutation associated phenotypes have been explored extensively since the molecular mechanism emerged involving elevated FMR1 messenger ribonucleic acid (mRNA) levels. Lowered fragile X mental retardation protein (FMRP) can also occur which may have an additive effect to the high levels of mRNA leading to neurodevelopmental problems and psychopathology. This paper was aimed to review psychosis and catatonia in premutation carriers, express the role of elevated FMR1 mRNA and lowered FMRP in the phenotype of carriers and present a case of psychosis and catatonia in a carrier. This case also demonstrates additional genetic and environmental factors which may also affect the phenotype. We review the literature and report an exemplary case of a 25 year old male premutation carrier with elevated FMR1 mRNA, low FMRP, a cytochrome P450 family 2 subfamily D polypeptide 6 (CYP2D6)*2xN mutation and a perinatal insult. This patient developed an autism spectrum disorder, psychosis, catatonia with subsequent cognitive decline after electro-convulsive therapy (ECT) for his catatonia. He had a premutation of 72 CGG repeat in FMR1, FMR1 mRNA level that was over 2.4 times normal and FMRP level at 18% of normal, and additionally, a CYP2D6 allelic variant which leads to ultrarapid metabolism (UM) of medication. There is an overlapping pathophysiological mechanism of catatonia and fragile X-associated premutation phenotypes including autism and psychosis. This case demonstrates the shared phenotype and the overlap of the pathophysiological mechanisms that can influence the intervention. Multiple genetic and environmental hits can lead to more significant involvement in premutation carriers.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561243PMC
http://dx.doi.org/10.5582/irdr.2015.01028DOI Listing

Publication Analysis

Top Keywords

psychosis catatonia
16
elevated fmr1
12
fmr1 mrna
12
catatonia fragile
8
fragile mental
8
mental retardation
8
catatonia premutation
8
premutation carriers
8
case demonstrates
8
genetic environmental
8

Similar Publications

Catatonia may manifest as an independent entity or as a feature of a neuropsychiatric or medical illness. While electroconvulsive therapy (ECT) is the gold standard treatment for catatonia, it is typically administered if the patient's symptoms fail to respond to benzodiazepines. We describe the case of a 22-year-old male with Budd Chiari induced cirrhosis and no prior psychiatric history, who presented with symptoms of psychosis and hepatic encephalopathy, was treated in the ICU for multi-factorial delirium, developed symptoms of catatonia that failed to respond to lorazepam, ultimately requiring ECT with a favorable response.

View Article and Find Full Text PDF

Autoimmune encephalitis (AE) tends to manifest as a mixture of neuropsychiatric and somatic symptoms, either of which may predominate, and often shows a progressive clinical course sometimes leading to life-threatening conditions. Catatonic and psychotic syndromes, regardless of whether associated with dysautonomia, are common manifestations of AE, especially concerning the anti-NMDAR subtype. Several autoantibodies targeting different neuronal epitopes have been linked to specific clinical manifestations and their detection is embedded in some of the diagnostic criteria for AE.

View Article and Find Full Text PDF

Psychiatric manifestations of encephalitis.

Ann Clin Transl Neurol

January 2025

Department of Neurology, Johns Hopkins Encephalitis Center, Johns Hopkin School of Medicine, Baltimore, Maryland, USA.

Objective: Encephalitis is a serious and potentially life-threatening condition of infectious or autoimmune cause. We aim to characterize the frequency and clinical spectrum of presenting psychiatric symptoms in encephalitis in order to inform earlier recognition and initiation of treatment.

Methods: This was a retrospective study of adult patients who met the 2013 International Encephalitis Consortium (IEC) and/or 2016 Graus criteria between February 2005 and February 2023.

View Article and Find Full Text PDF
Article Synopsis
  • An adolescent with ANMDAE and catatonia was treated with zolpidem after traditional treatments like benzodiazepines and ECT failed.
  • ANMDAE presents with neuropsychiatric symptoms, including memory issues, seizures, and catatonia, which can lead to serious medical complications.
  • Current guidelines offer limited options for treating catatonia in young patients who don't respond to standard treatments, and zolpidem may be a viable alternative.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!